Food and Drug Administration (FDA)Ĭalling on FDA to publicly address numerous concerns raised about approval requirements for generic versions of LIDODERM (lidocaine patch 5%). Securities and Exchange Commission.ĭuring first quarter 2012, Endo announced that it filed an amendment to its Citizen Petition (CP) with the U.S. changes that have been previously described in our filings with the U.S. Respect to royalty obligations among Endo, Hind Healthcare, Inc., and Teikoku Seiyaku Co., Ltd. The increase in LIDODERM net sales reflects changes as of mid-November 2011, with Net sales of LIDODERM® grew 11 percent on flat prescription growth. Endo expects our return to normal supply conditions and return to promotional activities to facilitate a return to growth for OPANA ER and Voltaren Gel for the remainder of 2012.
9, 2012, supplies of certain products including OPANA ER and Voltaren Gel were affected by the temporary closure of a OPANA ER net sales declined 4 percent and the company did not have any sales of Voltaren Gel. Now that there is better accessibility to OPANA ER and Voltaren Gel, physicians should feelĬonfident in prescribing these products for all appropriate patients.īranded pharmaceutical sales of $364 million for the first quarter 2012 represented a decrease of 3 percent versus the prior year. ∾ndos top priority is the health, well-being, and the continuity of care for our patients. Said Julie McHugh, chief operating officer at Endo. We are pleased to have these two important products back in steady supply across the country, TheĬompany believes there is adequate product available for all appropriate patients, both existing and new starts, following a short-term supply disruption announced in early January. TheĬompany recognized a liability under this agreement upon successfully demonstrating, in response to the Novartis supply disruption, the ability to accelerate the manufacture and sale of the new formulation of OPANA ER, which occurred in March 2012.Įndo also announced that it has now returned to steady supply of the new formulation of OPANA ER (oxymorphone HCL) designed to be crush-resistant and Voltaren Gel (diclofenac sodium topical gel) 1%.
#Endo pharma earnings license
Share includes the impact of a pre-tax charge in the amount of $110 million for the period to reflect a one-time payment that the company now expects to make to Impax per the terms of Endos 2010 settlement and license agreement with Impax. Services and execute our long-term vision of providing our customers with innovative healthcare solutions. We are keenly focused on execution that creates the opportunity for us to continue to grow our products and Temporary, constraints to supplies of some of our key pharmaceutical products, said Dave Holveck, president and CEO of Endo. Im extremely proud of the response by the organization in resolving the challenging, but Adjusted diluted earnings per share for first quarter 2012 were $0.87, down (Impax).Īdditionally, adjusted net income for the three months ended March 31, 2012, was $106 million, down 12 percent, compared with $120 million in the same period in 2011. The 2012 net loss was primarily driven by a one-time charge related to a first quarter 2012 accrual stemming from a 2010 litigation settlement with Impax Laboratories Inc. 31, 2012 of $87 million or $0.75 reported diluted loss per share, compared with net income of $56 million reported in theĬomparable 2011 period or $0.46 reported diluted earnings Endo incurred a net loss for the three months ended Mar. Of 2011, reflecting organic growth and the acquisition of AMS. Total revenues during the first quarter of 2012 increased 23 percent to $691 million, compared with $560 million in the same quarter OPANA ER and Voltaren Gel now in steady supply Resolving temporary supply disruption announced in early January.ĬHADDS FORD, Pa., May 1, 2012 Endo (Nasdaq: ENDP) today reported financial results for the first quarter Management expects return to year-over-year adjusted diluted earnings growth for remainder of 2012. Reported quarterly diluted loss per share of $0.75 versus earnings per share of $0.46 for prior year.
#Endo pharma earnings full
Total quarterly revenues of $691 million, increased 23 percent versus prior year Driven by full quarter addition of AMS as well asĪdjusted diluted EPS of $0.87, aligned with prior guidance of below $0.90. ENDO REPORTS FIRST QUARTER FINANCIAL RESULTS ANDĪNNOUNCES RETURN TO STEADY SUPPLY OF OPANA® ER AND
0 kommentar(er)
